TW202400621A - 經由超濾自血漿製備科恩池濃縮物之方法 - Google Patents

經由超濾自血漿製備科恩池濃縮物之方法 Download PDF

Info

Publication number
TW202400621A
TW202400621A TW112116169A TW112116169A TW202400621A TW 202400621 A TW202400621 A TW 202400621A TW 112116169 A TW112116169 A TW 112116169A TW 112116169 A TW112116169 A TW 112116169A TW 202400621 A TW202400621 A TW 202400621A
Authority
TW
Taiwan
Prior art keywords
plasma
cohen
protein
fraction
igg
Prior art date
Application number
TW112116169A
Other languages
English (en)
Chinese (zh)
Inventor
埃凡諾 馬特利
奧利佛 米瑟伯格
法蘭契絲卡 米切利
亞歷山大 澤登柏
傑洛 韓森
Original Assignee
日商武田藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商武田藥品工業股份有限公司 filed Critical 日商武田藥品工業股份有限公司
Publication of TW202400621A publication Critical patent/TW202400621A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/34Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026Blood substitute; Oxygen transporting formulations; Plasma extender
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/027Nanofiltration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14Ultrafiltration; Microfiltration
    • B01D61/145Ultrafiltration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D61/00Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/58Multistep processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D65/00Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
    • B01D65/02Membrane cleaning or sterilisation ; Membrane regeneration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2315/00Details relating to the membrane module operation
    • B01D2315/16Diafiltration
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2321/00Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/16Use of chemical agents
    • B01D2321/162Use of acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Water Supply & Treatment (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
TW112116169A 2022-05-02 2023-05-01 經由超濾自血漿製備科恩池濃縮物之方法 TW202400621A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263337439P 2022-05-02 2022-05-02
US63/337,439 2022-05-02
US202363498470P 2023-04-26 2023-04-26
US63/498,470 2023-04-26

Publications (1)

Publication Number Publication Date
TW202400621A true TW202400621A (zh) 2024-01-01

Family

ID=86646677

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112116169A TW202400621A (zh) 2022-05-02 2023-05-01 經由超濾自血漿製備科恩池濃縮物之方法

Country Status (9)

Country Link
US (1) US20250281530A1 (https=)
EP (1) EP4518875A1 (https=)
JP (1) JP2025514479A (https=)
KR (1) KR20250004876A (https=)
CN (1) CN119300842A (https=)
AU (1) AU2023264066A1 (https=)
MX (1) MX2024013454A (https=)
TW (1) TW202400621A (https=)
WO (1) WO2023215722A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) 1942-02-09 1945-12-04 Research Corp Protein product and process
DE2902158A1 (de) * 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US8304524B2 (en) * 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
SG187599A1 (en) * 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
US9403899B2 (en) * 2011-08-26 2016-08-02 Baxalta Incorporated Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii

Also Published As

Publication number Publication date
KR20250004876A (ko) 2025-01-08
JP2025514479A (ja) 2025-05-02
EP4518875A1 (en) 2025-03-12
MX2024013454A (es) 2024-12-06
CN119300842A (zh) 2025-01-10
WO2023215722A1 (en) 2023-11-09
US20250281530A1 (en) 2025-09-11
AU2023264066A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
AU2020200373B2 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
RU2266914C2 (ru) Способ получения igg
US20190169272A1 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
CA2941230C (en) Method for purifying immunoglobulin
CA2941232C (en) Method for purifying immunoglobulin
CN103476786B (zh) 一种生产血液来源蛋白质注射制剂的方法,以及使用上述方法获得的蛋白质物料
SK582002A3 (en) Process for the production of human gammaglobulin g and virus-inactivated human gammaglobulin g
AU2012300220B2 (en) Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
JP2014520829A (ja) 多価免疫グロブリン濃縮物の製造方法
KR20220161332A (ko) C-1 억제제 고갈 혈장으로부터 면역글로불린 조제물을 제조하는 방법
US20250281530A1 (en) Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration
TWI526214B (zh) 缺乏一種以上致血栓因子的血漿製品之製備方法
AU2015268579A1 (en) Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
EA045585B1 (ru) Способ получения препарата иммуноглобулина из плазмы с низким содержанием ингибитора c-1
Simon et al. Preparation of plasma derivatives
HK1199267B (en) Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition